In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …

Seven coronaviruses are known to cause infection/disease in humans. Of these, human
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …

Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern.
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages
that are more transmissible and resistant to currently approved antibody therapies poses a …

Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide
range of biomedical applications involving novel coronavirus disease (COVID-19) …